Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom

**Objective:** To evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2-) advanced breast cancer from a UK payer perspective. **Methods:** A co...

Full description

Saved in:
Bibliographic Details
Main Authors: Gaurav Suri, David Chandiwana, Adam Lee, Rohit Mistry
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2019-04-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/9725
Tags: Add Tag
No Tags, Be the first to tag this record!